Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRAX vs CELC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRAX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–2 Matrix Metrics)

PRAX Overall Winner 6-Pillar Tally: PRAX 4 – 0 CELC (2 Tie) Matrix Metrics: PRAX 4 – 2 CELC

As of Nov 16, 2026, Praxis Precision Medicines, Inc. (PRAX) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PRAX carries a Unified Composite Score of 34.6/100 (SELL) at $310.27 (N/M Forward P/E, 0.0% operating margin), whereas CELC carries 39.7/100 (SELL) at $60.57 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CELC currently prints a higher short-term Unified Composite Score (39.7/100 SELL vs. PRAX 34.6/100 SELL), PRAX captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+1349.1% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although PRAX compares more favorably head-to-head, both PRAX (34.6/100 SELL) and CELC (39.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: PRAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.6); meanwhile CELC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRAX vs CELC
PRAX NASDAQ Head-to-Head Winner
Praxis Precision Medicines, Inc. Common Stock
Pharmaceutical Preparations
$310.27
-5.44% 1D
Market Cap $9.2B
TTM Revenue $7.5M
Forward P/E N/M
Beta / 30D Vol 1.78β · 92% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $289.18 · SMA50: $289.00
CELC NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$60.57
-5.9% 1D
Market Cap $3.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 59% Vol
Unified Composite Score
39.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 59.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 38
RSI-14: 38.5 · SMA20: $66.12 · SMA50: $71.78

6-Pillar Scorecard Institutional Category Breakdown (PRAX 4 – 0 CELC)

Columns: Metric · PRAX · CELC
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PRAX
Revenue Growth (YoY) +1349.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.5M N/A
Market Cap $9.2B $3.1B
3. Profitability & Quality PRAX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -44.8% -1192.9%
4. Balance Sheet & Cash Flow PRAX
Cash Generation (TTM) -$324M -$264M
Cash Flow Margin N/A N/A
Net Cash / Leverage $361M Net Cash $577M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRAX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 103.0% (8th %ile) 84.0% (60th %ile)
Put/Call OI Skew 1.23x (Put-Skewed) 0.41x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRAX (4) vs CELC (2)
Institutional Metric PRAX CELC Criterion Row Edge
Market Capitalization
Scale
$9.2B $3.1B Larger Scale PRAX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1349.1% +0.0% Higher Growth PRAX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-44.8% -1192.9% Higher ROE PRAX
52-Week Range Position
Momentum
65% ($160–$393) 7% ($54–$151) Stronger Trend PRAX
Beta / 30D Volatility
Risk Regime
1.78β · 92% Vol 1.28β · 59% Vol Lower Realized Risk CELC
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 39.7 / 100 (SELL) Higher Composite CELC
Trailing 12M Revenue (USD)
Operating Scale
$7.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$324M ($361M Net Cash) -$264M ($577M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRAX +21.29 pp
PRAX: +28.34% · CELC: +7.05%
3M Horizon PRAX +18.93 pp
PRAX: -16.11% · CELC: -35.04%
6M Horizon PRAX +50.98 pp
PRAX: -3.2% · CELC: -54.18%
1Y Horizon PRAX +103.8 pp
PRAX: +74.23% · CELC: -29.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRAX vs CELC. Trailing 12-month operating profitability (PRAX 0.0% vs CELC 0.0%) and valuation multiples (PRAX N/M vs CELC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.5M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-44.8% · N/M
CELC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1192.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRAX CONSOLIDATION
67d in phase · OBV ACCUMULATION
Current IV 103.0%
IV Percentile 8th %ile
Put/Call OI Skew 1.23x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELC BREAKDOWN
136d in phase · OBV DISTRIBUTION
Current IV 84.0%
IV Percentile 60th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CELC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRAX vs CELC Key Questions & Quantitative Answers

As of Nov 16, 2026, Praxis Precision Medicines, Inc. (PRAX) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PRAX carries a Unified Composite Score of 34.6/100 (SELL) at $310.27 (N/M Forward P/E, 0.0% operating margin), whereas CELC carries 39.7/100 (SELL) at $60.57 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CELC currently prints a higher short-term Unified Composite Score (39.7/100 SELL vs. PRAX 34.6/100 SELL), PRAX captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+1349.1% vs. +0.0% YoY). Defensive Composite Rating Caution: Although PRAX compares more favorably head-to-head, both PRAX (34.6/100 SELL) and CELC (39.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: PRAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.6); meanwhile CELC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRAX leads the Growth & Scale pillar: PRAX posts +1349.1% YoY revenue growth and +0.0% YoY earnings growth on $7.5M TTM revenue (N/A gross margin, 0.0% operating margin), compared with CELC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRAX generates $7.5M in USD-normalized revenue versus N/A for CELC. In operating R&D and SG&A reinvestment, PRAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELC.

PRAX and CELC trade at balanced relative valuation multiples. PRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CELC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRAX (-44.8% ROE) versus CELC (-1192.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PRAX carries 103.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 1.23x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.78β · 92% Vol realized risk). By comparison, CELC carries 84.0% implied volatility (60th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.28β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.